Industry News

1 September 2025

Zydus's Saroglitazar shows positive results in Patients with Primary Biliary Cholangitis

Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.

1 September 2025

Astrazeneca's Baxdrostat reduces BP in patients with uncontrolled hypertension in clinical trials

Positive full results from the BaxHTN Phase III trial showed AstraZeneca baxdrostat, demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses 2mg and 1mg compared with placebo at 12 weeks. Results were seen in patients with hard-to-control uncontrolled and resistant hypertension who received baxdrostat or placebo on top of standard of care.

30 August 2025

FDA approves Teva's generic Weight loss medicine of Saxenda

Teva Pharmaceuticals, Inc. announced the FDA approval and U.S. launch of a generic version of Saxenda, liraglutide injection. first-ever generic GLP-1 indicated for weight loss

29 August 2025

Unichem Pharmaceuticals recall Cyclobenzaprine hydrochloride tablets due to mislabeling in USA

Unichem Pharmaceuticals (USA) is recalling one lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg because the Cyclobenzaprine 10mg (90ct) label was inadvertently placed on a bottle containing Meloxicam 7.5 mg tablets.

28 August 2025

Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options

Sandoz the global leader in generic and biosimilar medicines, today announced the launch of generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg and 20 mg. Rivaroxaban - 1 A Pharma® offers patients in Germany a high-quality, affordable alternative to reference product Xarelto®*, with a list price advantage across all three strengths.

27 August 2025

Dr. Reddy's launches Linaclotide (Colozo) a novel drug for Chronic Constipation management in adults, in India

Dr. Reddys Laboratories Ltd. announced the launch of Linaclotide, a first-in-class guanylate cyclase-C aganist for adults suffering from chronic constipation in India. Dr. Reddys becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo®, available in 72 mcg and 145 mcg strengths.

26 August 2025

CuraTeQ Biologics receives approval for biosimilar Dazublys from MHRA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency for Dazublys, its trastuzumab biosimilar version.

25 August 2025

Eris Lifesciences receives Brazilian approval at its Ahmedabad facility

Eris Lifesciences announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil’s national health regulatory agency.

22 August 2025

A potential way to relieve arthritic knees without drugs or surgery

Nearly a quarter of people over the age of 40 experience painful osteoarthritis, making it a leading cause of disability in adults. Osteoarthritis degrades joint-cushioning cartilage, and there is currently no way of reversing this damage: the only option is to manage pain with medication, and eventually, joint replacement.

22 August 2025

Combination Therapy Improves Outcomes for Advanced Triple-Negative Breast Cancer

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer, one of the most aggressive and hard-to-treat forms of breast cancer.

Search

Zydus's Saroglitazar shows positive results in Patients with Primary Biliary Cholangitis

RECOMMENDED POSTS

Subscribe with us

Jobs by Category